SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) was a Phase II multi-centre, single arm, non-randomised, open-label copper-64 labelled SAR-Bombesin PET imaging trial of ...
To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...
New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...
Rural men had almost twice the risk of prostate cancer biochemical recurrence as urban men in the US. Patients living in rural areas may be at an increased risk for prostate cancer biochemical ...
Changes in benign tissues next to prostate tumors may provide an early warning for patients at higher risk for biochemical recurrence after a radical prostatectomy, a study by researchers at Case ...
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
Radical prostatectomy does not ensure a cure, with one in three men experiencing cancer recurrence and elevated PSA levels within 10 years post-surgery. Significant side effects of prostate removal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results